Immunovant
IMVT
87 hedge funds and large institutions have $696M invested in Immunovant in 2020 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 0 closing their positions.
259% more capital invested
Capital invested by funds: $194M → $696M (+$502M)
164% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 11
118% more funds holding
Funds holding: 40 → 87 (+47)
20.02% more ownership
Funds ownership: 23.21% → 43.23% (+20%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.2M |
| 2 |
BlackRock
New York
|
+$30M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.8M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$28.3M |
| 5 |
RI
RTW Investments
New York
|
+$27.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$12M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$9.46M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$3.96M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.02M |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$1.8M |
IMVT Hedge Fund Activity: Q2 2020 in Review
87 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2020, worth a combined $696M — up 259% from $194M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new IMVT positions and 0 closed out — a net gain of 47 holders — while 29 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $36.2M. The largest seller was Ikarian Capital, cutting an estimated $12M.
- 87 institutional investors held Immunovant (IMVT) as of Q2 2020, up from 40 in Q1 2020.
- Funds reported $696M of Immunovant stock for Q2 2020, up 259% quarter-over-quarter.
- 47 funds opened new Immunovant positions in Q2 2020 and 0 closed out, a net change of +47 holders.
- The largest Immunovant buyer in Q2 2020 was Vanguard Group, an estimated $36.2M added.
- The largest Immunovant seller in Q2 2020 was Ikarian Capital, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2020.